Clinical trials: Systemic Lupus
Lupus Erythematosus, Systemic
Anti-ficolin-3 Autoantibodies in Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies. Antibodies against Ficolin-3 were previously identified in the sera of some SLE patients, but their…
- Trial name
- ficolupus (NCT02625831)
- Testing
- Biological analysis
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS)
A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders.
- Conditions
- Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS), Autoimmune Encephalitis
- Trial name
- ALLNEW (NCT07783269)
- Testing
- CTA313 UCAR T Cell Infusion
- Volunteers
- 81 people
- Sponsor
- Imviva Bio
Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms.
- Trial name
- NCT05879718
- Testing
- PF-06823859
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Pfizer
Systemic Lupus Erthematosus
Water-based Liuzijue Exercise on Childhood-onset Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a life-long systemic autoimmune disease with a large variability in its clinical course. The onset of SLE during childhood and adolescence represents 10 to 20% of all SLE cases [1] and is…
- Trial name
- NCT07024082
- Testing
- Land-based Liuzijue exercise, Water-based Liuzijue exercise
- Where
- Egypt
- Volunteers
- 130 people
- Sponsor
- MTI University
Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling
IL-26 and Systemic Lupus Erythematosus
Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy, underscoring the need to better dissection of the pathogenic mechanisms.
- Trial name
- NCT01889641
- Where
- France
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Systemic Lupus Erythematosus (SLE)
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC…
- Trial name
- NCT06144710
- Testing
- SG301 SC Injection
- Where
- 10 sites in China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Lupus Nephritis
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients
- Trial name
- NCT07767188
- Testing
- obinutuzumab (RO5072759)
- Where
- 14 sites in China
- Volunteers
- 70 people
- Sponsor
- Zhao Minghui
Lupus Nephritis
BAFF Levels and Lupus Nephritis (LN)
B-cell activating factor (BAFF), serves as a vital survival and differentiation factor for normal B-cell development. BAFF levels have been associated with the clinical activity of SLE in humans.
- Trial name
- BAFF (NCT04369495)
- Testing
- BAFF serum levels
- Sponsor
- Universidad de Antioquia
Systemic Lupus Erythematosus, COVID-19
Lupus Education Alliance Program
Randomized controlled trial of a COVID-19 behavioral and educational intervention for people with systemic lupus erythematosus (SLE).
- Trial name
- LEAP (NCT05243875)
- Testing
- LEAP Education + Navigation, LEAP Education
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Tulane University
Lupus Nephritis
The Iguratimod Effect on Lupus Nephritis (IGeLU)
This study is a 52-week, randomized, open, active-controlled trial of patients with active diffused lupus nephritis, to assess the efficacy and safety of a novel chemical synthetic agent iguratimod.
- Trial name
- IGeLU (NCT02936375)
- Testing
- Iguratimod, Cyclophosphamide, Azathioprine
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- RenJi Hospital
Systemic Lupus Erythematosus
Transcutaneous Vagus Nerve Stimulation in SLE
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease. Joint and muscle pain and fatigue are extremely common among patients and contribute to a reduced quality of life.
- Trial name
- TvSSLE (NCT06987565)
- Testing
- Active vagus nerve stimulation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwell Health
Systemic Lupus Erythematosus (SLE)
Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells
This study will investigate the safety and efficacy of allogeneic umbilical cord-derived stem cell therapy in treating patients with moderate to severe systemic lupus erythematosus.
- Trial name
- NCT07041801
- Testing
- hUC-MSCs treatment (low dose), hUC-MSCs treatment (medium dose), hUC-MSCs treatment (high dose)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Systemic Lupus Erythematosus
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
- Trial name
- SLE-BRAVE I (NCT03616912)
- Testing
- Baricitinib
- Where
- 184 sites in United States, Australia and 16 more
- Volunteers
- 830 people
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus
The Effect of Metformin on Reducing Lupus Flares
This is a multicenter, randomised, double-blind placebo controlled trial on the efficacy and safety of add-on metformin to conventional immunosuppressants in systemic lupus erythematosus (SLE).
- Trial name
- Met Lupus (NCT02741960)
- Testing
- metformin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- RenJi Hospital
Systemic Lupus Erythematosus, SLE
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
This is a phase IIb, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of orelabrutinib in adult subjects with SLE who are receiving standard of care (SOC) therapy.
- Trial name
- NCT05688696
- Testing
- Orelabrutinib (Low Dose), Orelabrutinib (High Dose)
- Where
- 41 sites in China
- Volunteers
- 186 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus, Lupus Nephritis
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
This is an open-label investigator-initiated trial (IIT) to assess the safety, efficacy, and PK（pharmacokinetic）/PD（pharmacodynamics ） of UB-VV410 in adult subjects with clinically active treatment-refractory SLE.
- Trial name
- NCT07109986
- Testing
- UB-VV410
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
SLE - Systemic Lupus Erythematosus
IASO-782 in Systemic Lupus Erythematosus
his study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with SLE. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of SLE.
- Trial name
- NCT07483346
- Testing
- IASO-782 injection
- Where
- 4 sites in China
- Volunteers
- 20 people
- Sponsor
- Shanghai IASO Biotechnology Co., Ltd
Systemic Lupus Erythematosus
Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
BACKGROUND AND RATIONALE. The role of type I interferons (IFN) in innate and adaptive immunity has been extensively studied, establishing a key role for type I IFNs in immune homeostasis.
- Trial name
- REVEAL (NCT07215754)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pisa
SLE, and Organ Damage Index
The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients
The goal of this observational study is to investigate if the 2019 EULAR/ACR classification criteria can be used to assess organ damage in patients with systemic lupus erythematosus (SLE) and as predictor for prognosis .
- Trial name
- NCT06313151
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Systemic Lupus Erythematosus
Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood
To assess how the absolute bioavailability, dose proportionality, pharmacokinetics, safety and tolerability of epratuzumab compared when given as a subcutaneous (sc) injection as to when given as an intravenous (iv) infusion in…
- Trial name
- NCT02306629
- Testing
- Epratuzumab sc, Epratuzumab iv
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.